Debio 0123
Oncology
Debio 0123 is a Wee1 kinase inhibitor. Wee1 is a key regulator of the G2/M and S phase checkpoints, activated in response to DNA damage, to allow cells to repair their DNA before resuming cycling. Inhibition of Wee1, particularly in combination with DNA damaging agents, induces an overload of DNA breaks, and in conjunction with abrogation of other checkpoints, such as G1 controlled by p53, pushes the cells through cycle without DNA repair, promotes mitotic catastrophe and induces apoptosis of cancer cells
Press Releases
-
April 1, 2019
Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…
-
June 20, 2017
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
Publications
-
April 2, 2019
Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123